147 related articles for article (PubMed ID: 15955377)
1. Influence of insulin treatment on insulin sensitivity in insulin requiring type 2 diabetes patients.
Mayorov AY; Naumenkova IV; Antsiferov MB; Dedov II
Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S54-9. PubMed ID: 15955377
[TBL] [Abstract][Full Text] [Related]
2. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
Rowe R; Cowx M; Poole C; McEwan P; Morgan C; Walker M
Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
[TBL] [Abstract][Full Text] [Related]
3. Insulin sensitivity in Type 1 diabetic children and adolescents.
Szadkowska A; Pietrzak I; Mianowska B; Bodalska-Lipińska J; Keenan HA; Toporowska-Kowalska E; Młynarski W; Bodalski J
Diabet Med; 2008 Mar; 25(3):282-8. PubMed ID: 18279410
[TBL] [Abstract][Full Text] [Related]
4. In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo?
Burén J; Lindmark S; Renström F; Eriksson JW
Metabolism; 2003 Feb; 52(2):239-45. PubMed ID: 12601640
[TBL] [Abstract][Full Text] [Related]
5. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute-phase proteins associate with glucose and lipid metabolism in healthy subjects.
Heliövaara MK; Teppo AM; Karonen SL; Tuominen JA; Ebeling P
Diabetes Obes Metab; 2005 Nov; 7(6):729-36. PubMed ID: 16219017
[TBL] [Abstract][Full Text] [Related]
6. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
[TBL] [Abstract][Full Text] [Related]
7. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
9. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
10. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
11. Oral magnesium supplementation in insulin-requiring Type 2 diabetic patients.
de Valk HW; Verkaaik R; van Rijn HJ; Geerdink RA; Struyvenberg A
Diabet Med; 1998 Jun; 15(6):503-7. PubMed ID: 9632126
[TBL] [Abstract][Full Text] [Related]
12. An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled Type 2 diabetic patients on oral hypoglycaemic agents: results of a feasibility study.
Aas AM; Bergstad I; Thorsby PM; Johannesen O; Solberg M; Birkeland KI
Diabet Med; 2005 Mar; 22(3):316-22. PubMed ID: 15717881
[TBL] [Abstract][Full Text] [Related]
13. Postprandial chylomicrons and adipose tissue lipoprotein lipase are altered in type 2 diabetes independently of obesity and whole-body insulin resistance.
Annuzzi G; Giacco R; Patti L; Di Marino L; De Natale C; Costabile G; Marra M; Santangelo C; Masella R; Rivellese AA
Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):531-8. PubMed ID: 18321693
[TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular risk factors and treatment with insulin in type II diabetic patients in whom oral hypoglycemic drugs have failed].
Calle Pascual AL; Calle Fernández JR
Med Clin (Barc); 1993 Jun; 101(5):165-7. PubMed ID: 8332008
[TBL] [Abstract][Full Text] [Related]
15. [The effect of a short-term reducing diet on the effect of insulin in type 2 diabetes mellitus].
Sindelka G; Skrha J; Hilgertová J; Justová V
Cas Lek Cesk; 1997 Sep; 136(17):530-2. PubMed ID: 9441013
[TBL] [Abstract][Full Text] [Related]
16. Impact of obesity on insulin action in NIDDM.
Campbell PJ; Carlson MG
Diabetes; 1993 Mar; 42(3):405-10. PubMed ID: 8432411
[TBL] [Abstract][Full Text] [Related]
17. Blood-glucose self-monitoring in insulin treated type 2 diabetes mellitus a cross-sectional study with an intervention group.
Schiel R; Müller UA; Rauchfub J; Sprott H; Müller R
Diabetes Metab; 1999 Sep; 25(4):334-40. PubMed ID: 10566123
[TBL] [Abstract][Full Text] [Related]
18. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
Hausmann M; Dellweg S; Osborn C; Heinemann L; Buchwald A; Rosskamp R; Genova P; Heise T
Diabetes Obes Metab; 2006 Sep; 8(5):574-80. PubMed ID: 16918593
[TBL] [Abstract][Full Text] [Related]
19. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
20. Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range.
Jani R; Molina M; Matsuda M; Balas B; Chavez A; DeFronzo RA; Abdul-Ghani M
Diabetes Care; 2008 Feb; 31(2):311-5. PubMed ID: 18000182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
